On Friday, Shares of Vale S.A. (NYSE:VALE), lost -0.76% to $5.23, after a Brazilian court ordered the company to halt operations at its nickel mine in the Amazons, Reuters reports.
Operations at the Onça Puma nickel mine, in the Pará state, faced regulatory scrutiny and protests seeking compensations, such as healthcare and better schools, for the indigenous communities in the region.
The court ordered Vale to give $287,000 for each village in the area until it creates a compensation program, Reuters added.
Vale S.A., together with its auxiliaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and internationally. Its Bulk Material segment produces and extracts iron ore and pellet.
Shares of Forward Industries Inc. (NASDAQ:FORD), inclined 21.15% to $1.26, during its last trading session, after the specialty and promotional products manufacturer stated its fiscal third quarter results.
Forward Industries stated earnings of 6 cents a share for the fiscal third quarter, up from break-even warnings in the year-ago quarter. Revenue fell to $7.23 million for the quarter from $9.06 million in the year-ago quarter.
There were no analysts’ estimates available for the company.
Forward Industries, Inc., together with its auxiliaries, designs, markets, and distributes carry and protective solutions primarily for hand held electronic devices.
Finally, Amarin Corporation plc (NASDAQ:AMRN), ended its last trade with 0.86% gain, and closed at $2.34.
Amarin Corporation declared the promotion of Joseph T. Kennedy to Executive Vice President, General Counsel and Planned Initiatives.
With more than 20 years of industry experience, Mr. Kennedy has contributed significantly to progress at Amarin since joining the company in December 2011 as Senior Vice President, General Counsel. Kennedy’s recent accomplishments comprise his role in leading Amarin to two noteworthy federal court rulings: The First Amendment-based federal court declaration allowing Amarin’s promotion of truthful and non-misleading off-label information about Vascepa® (icosapent ethyl) capsules and the first successful judicial challenge to a denial of five-year, NCE exclusivity since the Hatch-Waxman Act was passed in 1984. Kennedy is also credited with leading Amarin’s strategy in the successful prosecution of over 40 patents designed to protect the Vascepa franchise into 2030 and in the recent dismissal of a securities class action suit against Amarin. He also played an important role supporting Amarin business development in the establishment of Amarin’s U.S. Vascepa co-promotion agreement with Kowa Pharmaceutical America, Inc. and partnership agreement with Eddingpharm in greater China.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
